

Hall-2



09:40-09:50

Opening Ceremony

Keynote Forum

- 09:50-10:00 **Introduction**
- 10:00-10:35 **Paramjeet Kaur**
U.S. Food and Drug Administration, USA
- 10:35-11:35 **Workshop**
Jim Jingjun Huang
Ascendia Pharmaceuticals, USA

Group Photo

Networking & Refreshments 11:35-11:50 @ Foyer

Track 3: Contemporary Challenges of Drug Design, Discovery and Development

Track 7: Bioavailability, Bioequivalence and Drug Product Selection

Track 11: Clinical Pharmacology and Therapeutics

Track 12: Study Designs

Session Chair: Paramjeet Kaur, U.S. Food and Drug Administration, USA

Session Co-Chair: Aydin Erenmemisoglu, Novagenix Drug R&D Centre, Turkey

Session Introduction

- 11:50-12:20 **Bioequivalence of topical corticosteroids: Design and data analysis challenges with the vasoconstrictor assay**
Keith Gallicano, Novum Pharmaceutical Research Services, USA
- Prediction of *in-vivo* permeability, solubility, BCS-classing, food interactions, fraction absorbed and oral bioavailability using new *in-silico* methods and algorithms**
Urban Fagerholm, Prosilico, Sweden

Lunch Break 12:50-13:50 @ Athens

- 13:50-14:20 **Discovery of novel scaffolds for p²¹-activated kinase 4 inhibitors targeting C-terminal**
Dongmei Zhao, Shenyang Pharmaceutical University, China

Track 1: Emerging Bioavailability and Bioequivalence Studies

Track 5: Managing BA/BE Studies

Track 9: Need for Conducting BA/BE Studies

Track 13: Factors Affecting Bioavailability

Session Chair: Paramjeet Kaur, U.S. Food and Drug Administration, USA

Session Co-Chair: Aydin Erenmemisoglu, Novagenix Drug R&D Centre, Turkey

Session Introduction

- 14:20-14:50 **Optimizing formulation to maximize drug absorption from solution formulations**
Wenzhan Yang, Astra Zeneca Pharmaceuticals LP, USA
- Design, synthesis and studies of delta and Cox-2 receptor specific analgesic anti-inflammatory activity of some linear and cyclic peptides**
Subir Samanta, Birla Institute of Technology, India

Networking & Refreshments 15:20-15:35 @ Foyer

- 15:35-16:05 **The Bioequivalence of Citicoline 500mg film tablet**
Onursal Saglam, Novagenix Biyoanalitik Ilac, Turkey
- 16:05-16:35 **Possible mistakes and manipulations in bioequivalency trials**
Aydin Erenmemisoglu, Novagenix Drug R&D Centre, Turkey
- Mexico and Brazil: Lands for bioequivalence testing and generic product registration IFaB as a choice for your trials in Mexico and Brazil**
Marlene Teresa Llopiz-Aviles, Harvard University School of Public Health, USA

Panel Discussion

Day 2 August 18, 2015

Hall-2

Track 2: Bioanalytical Methodology

Track 4: Regulatory Policies, Procedures and Prerequisites for Clinical Research

Track 6: Relevance of Genetics to BA/BE in Drug Development

Track 8: Advances in Assessment of Bioequivalence

Track 10: Metabolic Pathways and Changes in Nutrient Bioavailability

Session Chair: **Subrata Deb**, Roosevelt University College of Pharmacy, USA

Session Co-Chair: **Dongmei Zhao**, Shenyang Pharmaceutical University, China

Session Introduction

- 10:00-10:30 **Effect of formulation development and API characteristics on fast dissolving dosage forms bioequivalence studies**
Gulay Yelken Demirel, Sanovel Pharmaceuticals, Turkey
- 10:30-11:00 **Oral bioavailability and gender-related pharmacokinetics of Celastrol following administration of pure celastrol and its related tablets in rats**
Wenzheng Ju, Jiangsu Provincial Hospital of Traditional Chinese Medicine, China
- 11:00-11:30 **Preparation and *in-vitro* evaluation of meloxicam co-ground mixtures**
Aly H Nada, Kuwait University, Kuwait

Networking & Refreshments 11:30-11:45 @ Foyer

- 11:45-12:15 **Impact of glucocorticoids on the bioavailability and metabolism of Abiraterone and Calcitriol**
Subrata Deb, Roosevelt University College of Pharmacy, USA
- 12:15-12:45 **Comparative analysis, target specificities and plant protection potential of antimicrobial peptides isolated from *xenorhabdus* species**
Andras Fodor, University of Wisconsin-Madison, USA

Lunch Break 12:45-13:45 @ Athens

- 13:45-14:15 **E-BABE- A bioequivalence study of two Nicotine 2mg Lozenge formulations in healthy adult Indian human male smoker subjects**
Muneesh Garg, Sitec Labs Pvt Ltd, India
- 14:15-14:45 **Eprosartan mesylate cocrystals and their enhanced oral bioavailability studies**
Jaswanth Santosh Bhandaru, Kakatiya University, India
- 14:45-15:15 ***In-vitro* bioequivalence studies in tablet formulation containing 625mg of Colesevelam hydrochloride**
Gulcin Tok, Sanovel Pharmaceuticals, Turkey

Networking & Refreshments 16:15-16:30 @ Foyer

Panel Discussion

Day 3 August 19, 2015

Hall-2

Introduction

10:00-11:00 **Business to Business Meetings(B2B)**

Networking & Refreshments Break 11:00-11:15 @ Foyer

11:15-12:30 **Academics & Research Meetings**

Networking & Lunch Break 12:30-13:30 @ Athens

Closing Ceremony

Bookmark your dates

4th Annual

European Pharma Congress

June 13-15, 2016 Berlin, Germany

Website: europe.pharmaceuticalconferences.com

e-mail: pharmaeurope@conferenceseries.com; pharmaeurope@conferenceseries.net

7th Annual

Global Pharma Summit

August 01-03, 2016 Toronto, Canada

Website: american.pharmaceuticalconferences.com

e-mail: americanpharma@conferenceseries.com; americanpharma@conferenceseries.net

7th World Congress on

Bioavailability & Bioequivalence: BA/BE Studies Summit

August 29-31, 2016 San Francisco, USA

Website: bioavailability-bioequivalence.pharmaceuticalconferences.com

e-mail: babe@conferenceseries.net; babe@conferenceseries.com



OMICS Group Inc.

2360 Corporate Circle, Suite 400
Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169
Fax: +1-650-618-1417
contact@omicsgroup.com

OMICS International

5716 Corsa Ave., Suite 110, Westlake
Los Angeles, CA 91362-7354, USA
Ph: +1-650-268-9744
Fax: +1-650-618-1414
contact.americas@omicsonline.org

OMICS Group

SEZ Unit, Building No. 20, 9th Floor
APIIC Layout, HITEC City
Hyderabad-500081, Telangana, INDIA
Ph: 040-40131823, 040-47482222
contact.asiapacific@omicsonline.org

Toll free

USA & Canada: +1-800-216-6499
Australia: +1-800-651-097
Europe: 0805-080048